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Association of Comorbidity Burden With Abnormal Cardiac
Mechanics: Findings From the HyperGEN Study
Senthil Selvaraj, MD, MA; Frank G. Aguilar, MPH; Eva E. Martinez, BA; Lauren Beussink, MHS, RDCS; Kwang-Youn A. Kim, PhD;
Jie Peng, MS; Laura Rasmussen-Torvik, PhD; Jin Sha, MS; Marguerite R. Irvin, PhD; C. Charles Gu, PhD; Cora E. Lewis, MD, MSPH;
Steven C. Hunt, PhD; Donna K. Arnett, PhD, MSPH; Sanjiv J. Shah, MD, FAHA
Background-—Comorbidities are common in heart failure (HF), and the number of comorbidities has been associated with poor
outcomes in HF patients. However, little is known about the effect of multiple comorbidities on cardiac mechanics, which could
impact the pathogenesis of HF. We sought to determine the relationship between comorbidity burden and adverse cardiac
mechanics.
Methods and Results-—We performed speckle-tracking analysis on echocardiograms from the HyperGEN study (n=2150). Global
longitudinal, circumferential, and radial strain, and early diastolic (e’) tissue velocities were measured. We evaluated the association
between comorbidity number and cardiac mechanics using linear mixed effects models to account for relatedness among subjects.
The mean age was 5114 years, 58% were female, and 47% were African American. Dyslipidemia and hypertension were the most
common comorbidities (61% and 58%, respectively). After adjusting for left ventricular (LV) mass index, ejection fraction, and
several potential confounders, the number of comorbidities remained associated with all indices of cardiac mechanics except
global circumferential strain (eg, b=0.32 [95% CI 0.44, 0.20] per 1-unit increase in number of comorbidities for global
longitudinal strain; b=0.16 [95% CI 0.20, 0.11] for e’ velocity; P≤0.0001 for both comparisons). Results were similar after
excluding participants with abnormal LV geometry (P<0.05 for all comparisons).
Conclusions-—Higher comorbidity burden is associated with worse cardiac mechanics, even in the presence of normal LV
geometry. The deleterious effect of multiple comorbidities on cardiac mechanics may explain both the high comorbidity burden
and adverse outcomes in patients who ultimately develop HF. ( J Am Heart Assoc. 2014;3:e000631 doi: 10.1161/
JAHA.113.000631)
Key Words: cardiac mechanics • comorbidities • echocardiography • risk factors • strain
T he progression from cardiac risk factors to heart failure istypically mediated by an asymptomatic stage in which
structural and/or functional left ventricular (LV) abnormalities
can be discerned, highlighting a prime opportunity for both
prevention of further progression and intervention.1 Previous
studies have emphasized, in particular, the effects of cardiac
and non-cardiac comorbidities on abnormal LV geometry,
considered both in isolation and in concert with other
comorbidities.2–8 The addition of comorbidities results in a
progressive increase in LV mass, a major risk factor for future
adverse cardiovascular events.9 However, prior to overt
cardiac remodeling or reduced ejection fraction detected by
conventional 2-dimensional (2D) echocardiography, speckle-
tracking echocardiography can detect subclinical alterations in
cardiac performance by examining intrinsic indices of cardiac
mechanics (LV strain and tissue velocities). Understanding the
link between comorbidity burden and cardiac mechanics may
explain why an increasing number of comorbidities predicts
hospitalization in patients with heart failure.10
The evaluation of echocardiograms from the Hypertension
Genetic Epidemiology Network (HyperGEN) study permits
comprehensive assessment of the relationship between
comorbidities and cardiac mechanics. Strengths of the
HyperGEN study for studying mechanical alterations include
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a large bi-racial sample of >2000 participants, comprehensive
clinical and laboratory data collection, and 2-dimensional (2D)
and Doppler echocardiographic data.11 Speckle-tracking
analysis has now allowed for the measurement of indices of
cardiac mechanics in HyperGEN.
Therefore, we sought to determine whether comorbidity
burden (ie, number of comorbidities) is associated with
incremental worsening of cardiac mechanics. We hypothe-
sized that accumulation of comorbidities is associated with
worse cardiac mechanics (decreased LV strain and early
diastolic [e’] tissue velocities), independent of its effects on




HyperGEN, part of the National Institutes of Health Family
Blood Pressure Program (FBPP), is a cross-sectional study
consisting of 5 US sites, with 4 participating in an ancillary
echocardiographic study (Salt Lake City, UT; Forsyth County,
NC; Minneapolis, MN; and Birmingham, AL). The goal of
HyperGEN was to identify and characterize the genetic basis
of familial hypertension; the complete details of the HyperGEN
study design have been reported previously.11 Study eligibility
required a diagnosis of hypertension prior to the age of 60 and
at least 1 sibling willing to participate in the study. Hyperten-
sion was deﬁned by an average systolic blood pressure
≥140 mm Hg or an average diastolic blood pressure
≥90 mm Hg (on at least 2 separate clinic visits) or by self-
reporting treatment for hypertension. A random sample of
normotensive individuals who represented the source cohort
from which the HyperGEN affected sibships were identiﬁed
was also recruited. Individuals with a history of type 1
diabetes mellitus or severe chronic kidney disease were
excluded due to the high risk of secondary forms of
hypertension. None of the study participants had symptomatic
heart failure. All HyperGEN study participants gave written
informed consent, and the HyperGEN study was approved by
each study site’s local institutional review board.
Clinical Characteristics and Deﬁnition of
Comorbidity Burden
Demographic, clinical, and laboratory data were collected
during the initial HyperGEN visit. Height, weight, blood
pressure, and waist circumference were measured by trained
personnel, using a standardized protocol. Three sitting, upright
blood pressure measurements were obtained per person and
averaged; further details regarding blood pressure measure-
ments have been previously reported.11 Histories of
myocardial infarction, transient ischemic attack, or stroke
were obtained by self-report. Diabetes mellitus was deﬁned by
fasting glucose ≥126 mg/dL, use of hypoglycemic medication,
or a self-reported history. Dyslipidemia was deﬁned by use of
lipid-lowering medication, low-density lipoprotein cholesterol
≥160 mg/dL, triglycerides >150 mg/dL, or high-density lipo-
protein cholesterol <40 mg/dL (for men) or <50 mg/dL (for
women). Obesity was deﬁned by a body mass index ≥30 kg/
m2. Chronic kidney disease was deﬁned by an estimated
glomerular ﬁltration rate ≤60 mL/min per 1.73 m2.
Comorbidity burden was deﬁned as the number of the
following comorbidities: hypertension, dyslipidemia, obesity,
diabetes mellitus, chronic kidney disease, coronary artery
disease, and transient ischemic attack/stroke.
Echocardiography
Echocardiography (including 2D, M-mode, and Doppler imag-
ing) was acquired on all study participants using standardized
acquisition protocols and stored in analog format (high grade,
medical quality videocassette tapes) at the time of study
visit.12,13 Cardiac structure and function were quantiﬁed as
recommended by the American Society of Echocardiography
(ASE).14,15 LV ejection fraction was calculated using the
biplane method of discs. LV mass was calculated using the
linear method recommended by the ASE and indexed to body
surface area. LV hypertrophy was deﬁned by a LV mass index
>95 g/m2 in women or >115 g/m2 in men. Normal geometry
was deﬁned by the absence of LV hypertrophy. Diastolic
function was quantitated using early diastolic (E) and late/
atrial diastolic (A) transmitral velocities, E/A ratio, isovolumic
relaxation time, and E deceleration time.
Digitization of Echocardiograms and
Interpretation of Image Quality
Archived echocardiograms in analog format were converted to
digital format using the TIMS 2000 DICOM System (Foresight
Imaging). Cine loopsof2 to4cardiac cycles fromtheparasternal
short axis (papillary muscle level) and apical 4-chamber views
were digitized at a high rate and stored ofﬂine in DICOM format.
Each study was assessed for image quality by an experienced
operator, blinded to all other clinical and echocardiographic
data, using a 4-point scale based on the degree of endocardial
border visualized (1=0% to 25%; 2=25% to 50%; 3=50% to 75%;
4=75% to 100%), similar to scales used previously.16,17
Two-Dimensional Speckle-Tracking Analysis
Digitized cine loops were analyzed using 2D wall motion
tracking software (2D Cardiac Performance Analysis [CPA],
TomTec v4.5). After isolating the highest quality cardiac cycle,
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the endocardial and epicardial borders were traced at end-
systole in each view. Computerized speckle-tracking analysis
was performed and endocardial and epicardial border tracings
were manually adjusted to optimize tracking. Indices of LV
mechanics included peak global longitudinal strain (GLS),
peak global radial strain (GRS), peak global circumferential
strain (GCS), and early diastolic (e’) tissue velocities. LV ﬁlling
pressures were estimated using E/e’ ratio. For ease of
display, all strain values were converted to absolute values (ie,
longitudinal and circumferential strain values were converted
from negative to positive values). Lower absolute strain
values, lower e’ tissue velocities, and higher E/e’ ratio were
used to indicate worse cardiac function. A validation of the
digitization and speckle-tracking techniques employed here
have been published elsewhere.18 Intra- and inter-observer
reliability data for speckle-tracking measurements in Hyper-
GEN were excellent, as detailed previously.19
Statistical Analysis
Clinical characteristics, laboratory data, and both conven-
tional echocardiographic parameters and speckle-tracking
parameters are displayed for the total cohort. Continuous
data are presented as meanstandard deviation. Categorical
variables are presented as a count and percentage.
We performed multivariable analyses to determine whether
number of comorbidities is associated with worse indices of
cardiac mechanics and increased LV ﬁlling pressure (ie, E/e’
ratio) after accounting for potential confounders. We used
linear mixed effects models, thereby accounting for related-
ness among HyperGEN participants. Analyses were repeated
after excluding participants with a prior history of myocardial
infarction to determine whether number of non-cardiac
comorbidities is associated with worse indices of cardiac
mechanics and increased LV ﬁlling pressure. Further analyses
were performed in participants with normal LV geometry.
Multivariable-adjusted logistic mixed effects models were
used to determine which comorbidities predicted abnormal
GLS by the ASE deﬁnition (<12%).20 For the outcome of
abnormal GLS, we performed additional analyses to explore
whether a weighted comorbidity index would perform better
than equal weighting of comorbidities. We performed a logistic
regression analysis with abnormal GLS (<12%) as the depen-
dent variable and individual comorbidities as the independent
variables. Next, we created a weighted comorbidity index based
on the model coefﬁcients for each of the comorbidities. Finally,
we compared the un-weighted comorbidity index with the
weighted comorbidity index with receiver operating character-
istic (ROC) analyses.
For our multivariable analyses, Model 1 included speckle-
tracking analyst, image quality, and center (as well as familial
relatedness, which was entered into the model as a random
effect). Model 2 included all Model 1 covariates plus age, sex,
race, LV mass index, ejection fraction, and wall motion score
index. We also conducted subgroup analyses with participants
stratiﬁed by race and sex. Multiplicative interaction terms
were created and entered into regression models to deter-
mine whether there were interactions between comorbidity
burden and race/sex.
A 2-sided P value <0.05 was considered statistically
signiﬁcant. Analysis was performed using Stata v.12 (Stata-
Corp) and SAS v. 9.0 (SAS Institute).
Results
Characteristics of Study Participants
Descriptive characteristics of the study sample from Hyper-
GEN are displayed in Table 1. The study cohort consisted of
2150 participants, randomly sampled from all 4 participating
sites, representing 1089 unique families. The mean age was
5114 years, 58% were female, 47% were African American,
and 53% were white. Recruitment was relatively split among
the 4 centers. Comorbidities were common; only 14% of study
participants were free of comorbidities, and most participants
had 1 or 2 comorbidities. Figure 1 displays the histograms
of number of comorbidities, stratiﬁed by sex and race. In
participants with 1 or 2 comorbidities, dyslipidemia, obesity,
and hypertension were the most common risk factors.
Notably, 131 (6%) of the study participants had a history of
myocardial infarction, and 134 (6%) had a history of coronary
revascularization (coronary artery bypass surgery, angioplasty,
or stent). Medication use reﬂected standard therapies used
in the comorbidities detailed in Table 1. Calcium channel
blockers (23%) and angiotensin-converting enzyme inhibitors
(21%) were the most commonly employed anti-hypertensive
therapies. Blood pressure was relatively well controlled
(12721/7211 mm Hg), and obesity was common (mean
body mass index 317 kg/m2, 47% obese [BMI>30 kg/m2]).
Laboratory results revealed preserved kidney function (esti-
mated glomerular ﬁltration rate 8520 mL/min per 1.73 m2)
in the majority of study participants.
Table 2 lists the 2D, Doppler, and speckle-tracking echo-
cardiographic parameters of the study participants. Average LV
structure fell within normal limits (LV end-systolic volume
5123 mL; LV end-diastolic volume 13031 mL; LV mass
index 8522 kg/m2), though roughly one-ﬁfth had evidence of
LV hypertrophy (22%). Global LV systolic function was pre-
served (ejection fraction 628%) in themajority of participants.
Images used for speckle-tracking analysis were generally
of high quality. In the parasternal short-axis and apical 4-
chamber views, 85% and 97% of images had an image quality
score of ≥2, respectively, indicating good image quality for the
majority of myocardial segments. The values obtained for
DOI: 10.1161/JAHA.113.000631 Journal of the American Heart Association 3
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Recruiting center, n (%)
Birmingham, AL 590 (27)
Minneapolis, MN 426 (20)
Salt Lake City, UT 589 (27)





Diabetes mellitus 365 (17)
Chronic kidney disease 197 (9)
Myocardial infarction 131 (6)
Transient ischemic attack or stroke 97 (5)








Anti-hypertensive medication 1095 (51)
Angiotensin-converting enzyme inhibitor 444 (21)
Alpha blocker 168 (8)
Angiotensin receptor blocker 54 (3)
Beta-blocker 275 (13)
Calcium channel blocker 488 (23)
Loop diuretic 141 (7)
Thiazide diuretic 275 (13)
Hypoglycemic medication 226 (11)
Insulin 85 (4)
Lipid lowering medication 197 (9)
Statin 174 (8)
Physical examination
Systolic blood pressure, mm Hg 12721






Body-mass index, kg/m2 317




Estimated glomerular filtration rate, mL/
min per 1.73 m2
8520
Fasting glucose, mg/dL 10643
Total serum cholesterol, mg/dL 19639
High density lipoprotein, mg/dL 5115
Low density lipoprotein, mg/dL 11934
Triglycerides, mg/dL 14098
Figure 1. Histogram plots of number of comorbidities stratiﬁed
by sex and race. Stratiﬁed by sex (top panel) and race (bottom
panel). There were no signiﬁcant differences in number of
comorbidities by sex (P=0.07) or race (P=0.58).
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most strain parameters were lower (ie, worse) than values
obtained in patients with mild hypertension.21 By ASE
standards, 20% had abnormally low GLS.
Association of Number of Comorbidities With
Worse Cardiac Mechanics and Higher LV Filling
Pressures
Figure 2 displays bar graphs demonstrating the relationship
between number of comorbidities and progressively worse
GLS, GCS, and GRS (P<0.001 for trend). Figure 3 shows a
similar relationship of comorbidity burden with diastolic
parameters (e’ velocity and E/e’ ratio) (P<0.001 for trend).
Table 3 demonstrates the strength these associations. After
adjusting for factors that could have affected the measure-
ment of speckle-tracking parameters (Model 1; covari-
ates=speckle-tracking analyst, recruitment center, and
image quality), comorbidity burden was still associated with
GLS, tissue e’ velocity, and E/e’ ratio (P<0.0001 for all
associations). For instance, for each 1-unit increase in the
number of comorbidities, GLS decreased by 0.41%-units.
These ﬁndings were consistent in both the entire cohort and
in study participants with normal LV geometry. Table 4 shows
that the ﬁndings were similar even after further adjustment
for additional covariates (Model 2), including age, sex, race,
wall motion score index, LV mass index, and ejection fraction.
Further adjustment for smoking status, systolic blood
pressure, and number of anti-hypertensive medications did
not attenuate the key associations between comorbidity
burden and GLS (P=0.004), e’ velocity (P<0.0001), and E/e’
ratio (P<0.0001). Excluding participants with a prior history of
myocardial infarction resulted in similar ﬁndings (Table 5).
Table 2. Two-Dimensional, M-Mode, Doppler, and Speckle-





LV end-diastolic volume, mL 13031
LV end-systolic volume, mL 5123
LV mass index, g/m2 8522
LV hypertrophy, n (%) 469 (22)
Left atrial diameter, cm 3.50.5
LV ejection fraction, % 628
Stroke volume, mL 7616
Cardiac index, L/min per m2 2.60.6
Early (E) transmitral velocity, cm/s 7320
Late/atrial (A) transmitral velocity, cm/s 6619
E/A ratio 1.190.50
E deceleration time, ms 20458
Isovolumic relaxation time, ms 8018
Speckle-tracking echocardiographic parameters
e’ velocity, cm/s* 3.51.3
E/e’ ratio* 23.811.9
Global radial strain, % 26.611.9
Global circumferential strain, % 20.65.3
Global longitudinal strain, % 14.63.6
LV indicates left ventricular.
*Tissue velocity values derived from speckle-tracking software are lower than values





Figure 2. Bar graphs of number of comorbidi-
ties vs indices of cardiac mechanics. Increasing
comorbidity burden is associated with worsening
global longitudinal strain (A), global circumferen-
tial strain (B), and global radial strain (C). P values
represent signiﬁcance for the trend across num-
ber of comorbidities. Error bars represent stan-
dard errors.
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Table 6 demonstrates the association of number of
comorbidities with cardiac mechanics and LV-ﬁlling pressure
stratiﬁed by race/ethnicity. The effect sizes demonstrated
by the beta-coefﬁcients in Table 6 demonstrate that for
every 1-unit increase in the number of comorbidities, African
Americans (compared with whites) had disproportionately
worse GLS and GRS, and higher LV-ﬁlling pressure (E/e’
ratio). In addition, the association of number of comorbid-
ities with GRS was only signiﬁcant in the African-American
subgroup. African-American participants were more likely to
be obese compared with whites (52% versus 43%, respec-
tively). However, additional adjustment for body mass index
in our multivariable models did not change the differential
associations between comorbidity burden and cardiac
mechanics by race. Race9comorbidities interaction testing
demonstrated that there was a signiﬁcant interaction
(P<0.05) between race and comorbidity burden for GLS,
GCS, and E/e’ ratio (Table 6). Table 7 lists the demographic
and comorbidity differences between whites and African
Americans. We found no sex-based differences in the
association of number of comorbidities with cardiac
mechanics (interaction P>0.10 for all indices of cardiac
mechanics).
Independent Predictors of Abnormal Global
Longitudinal Strain
Table 8 displays the odds ratios for each comorbidity, as well
as number of comorbidities, in predicting abnormal GLS
(<12%) on mixed-effects logistic regression analyses (adjusted
for all factors in Model 2). After multivariable adjustment,
only obesity (odds ratio 1.31 per comorbidity, P=0.049) and
number of comorbidities (odds ratio 1.22 per comorbidity,
P=0.0009) were independently associated with abnormal
GLS. We found that a weighted comorbidity index (more
weight given to those comorbidities that were more closely
associated with abnormal GLS) was only slightly better than
the unweighted comorbidity index (c-statistic=0.62 versus
0.61, respectively; P=0.006).
Discussion
In a speckle-tracking study of 2150 HyperGEN participants,
we found that comorbidity burden was associated with several
Table 3. Association of Number of Comorbidities With Cardiac Mechanics and Filling Pressures After Multivariable Adjustment
(Model 1)*
Dependent Variable
All Participants (n=2150) Participants With Normal Left Ventricular Geometry (n=1620)
b-Coefﬁcient (95% CI) P Value b-Coefﬁcient (95% CI) P Value
Global radial strain, % 0.19 (0.59, 0.20) 0.34 0.14 (0.60, 0.32) 0.54
Global circumferential strain, % 0.05 (0.13, 0.22) 0.58 0.18 (0.01, 0.39) 0.06
Global longitudinal strain, % 0.41 (0.52, 0.30) <0.0001 0.32 (0.44, 0.19) <0.0001
e’ velocity, cm/s 0.36 (0.41, 0.32) <0.0001 0.36 (0.41, 0.31) <0.0001
E/e’ ratio 2.69 (2.16, 3.22) <0.0001 2.19 (1.64, 2.72) <0.0001
*Adjusted for speckle-tracking analyst, recruiting center, image quality.
(A)
(B)
Figure 3. Bar graphs of number of comorbidities
vs diastolic parameters. Increasing comorbidity
burden is associated with worsening e’ velocity (A)
and progressively increased E/e’ ratio (B), an index of
increase left ventricular ﬁlling pressure. P values
represent signiﬁcance for the trend across number of
comorbidities. Error bars represent standard errors.
*Values for speckle tracking-derived e’ velocity are
lower (and therefore E/e’ are higher) than those
obtained clinically (via tissue Doppler imaging).
DOI: 10.1161/JAHA.113.000631 Journal of the American Heart Association 6
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indices of abnormal cardiac mechanics and higher LV-ﬁlling
pressures in a dose-response fashion. The ﬁndings were
signiﬁcant after controlling for LV ejection fraction and LV
mass index and even in participants without evidence of LV
remodeling by conventional echocardiography. To our knowl-
edge, our study is one of the largest speckle-tracking
investigations to date and is the ﬁrst to show the adverse
effects of comorbidity burden on intrinsic measures of
myocardial function.
Our ﬁndings are clinically relevant. Based on prior studies
relating GLS to outcomes, the differences in GLS across the
number of comorbidities is clinically signiﬁcant. Studies have
shown that for every 1% worsening in GLS, the risk of adverse
outcomes increases by 18% to 28%.22,23 Furthermore, the 4%
worsening in GLS detected between participants with the
lowest (0) and highest (5+) number of comorbidities has been
found to be associated with an adjusted hazard ratio of 1.45
for increased mortality.24
The association of comorbidity burden with worse GLS is
likely explained by the vulnerability of the subendocardium.
Longitudinal LV mechanics, which are largely determined by
the subendocardium, are the most sensitive and vulnerable to
myocardial disease processes.25 Diastolic indices of impaired
relaxation and increased ﬁlling pressures are likewise sensi-
tive indicators of cardiac function, which often precede overt
diastolic dysfunction.25 Though abnormalities in GRS and
GCS, which both evaluate transmural function, often occur
later in disease processes, the reason why only one (GRS)
correlated well with comorbidity burden remains unclear,
though the lack of association between comorbidities and
GCS may have been due to the decreased accuracy of post-
hoc speckle-tracking GCS compared with prospective, native
GCS.18
The ﬁnding in our subgroup analysis that African Americans
are disproportionately affected by comorbidity burden is
particularly notable. African Americans develop heart failure
at the highest incidence rate in the United States and show
symptoms at early ages.26,27 Increased comorbidity burden
has been hypothesized as one etiology.26 We provide further
evidence here for the role of comorbidities in disproportionate
cardiac dysfunction in African-American adults. In our
subgroup analyses, we found that the magnitude of the
association between comorbidity burden and worse cardiac
mechanics (GLS and GCS) and higher E/e’ ratio was greater in
African Americans compared with whites, as demonstrated by
differences in effect sizes and signiﬁcant interaction P values.
Though African Americans develop LV hypertrophy more
commonly than whites,28 our analyses, which controlled for
Table 4. Association of Number of Comorbidities With Cardiac Mechanics and Filling Pressures After Multivariable Adjustment
(Model 2)*
Dependent Variable
All Participants (n=2150) Participants With Normal Left Ventricular Geometry (n= 1620)
b-Coefﬁcient (95% CI) P Value b-Coefﬁcient (95% CI) P Value
Global radial strain, % 0.49 (0.93, 0.06) 0.02 0.52 (1.02, 0.03) 0.04
Global circumferential strain, % 0.02 (0.16, 0.20) 0.83 0.02 (0.19, 0.22) 0.87
Global longitudinal strain, % 0.32 (0.44, 0.20) <0.0001 0.29 (0.42, 0.16) <0.0001
e’ velocity, cm/s 0.16 (0.20, 0.11) <0.0001 0.15 (0.20, 0.10) <0.0001
E/e’ ratio 1.53 (0.96, 2.11) <0.0001 1.45 (0.86, 2.02) <0.0001
*Adjusted for speckle-tracking analyst, recruiting center, image quality, age, sex, race, left ventricular mass index, wall motion score, and ejection fraction.
Table 5. Association of Number of Comorbidities With Cardiac Mechanics and Filling Pressures After Multivariable Adjustment—
Excluding Participants With Prior Myocardial Infarction (Model 2)*
Dependent Variable
All Participants (n=2019) Participants With Normal Left Ventricular Geometry (n=1551)
b-Coefﬁcient (95% CI) P Value b-Coefﬁcient (95% CI) P Value
Global radial strain, % 0.46 (0.91, 0.00) 0.048 0.46 (0.96, 0.5) 0.08
Global circumferential strain, % 0.04 (0.15, 0.23) 0.68 0.04 (0.17, 0.25) 0.69
Global longitudinal strain, % 0.33 (0.45, 0.21) <0.0001 0.29 (0.43, 0.16) <0.0001
e’ velocity, cm/s 0.16 (0.21, 0.12) <0.0001 0.16 (0.21, 0.11) <0.001
E/e’ ratio 1.60 (1.01, 2.18) <0.0001 1.54 (0.95, 2.13) <0.0001
*Adjusted for speckle-tracking analyst, recruiting center, image quality, age, sex, left ventricular mass index, wall motion score, and ejection fraction.
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LV mass index, show that intrinsic inequalities in myocardial
mechanics related to comorbidity burden may also play a role
in the racial disparities in heart failure development and
severity. The results shown in Table 7 suggest that race/
ethnic differences in the pattern of comorbidities may also
play a role in the greater role of comorbidities on cardiac
mechanics in African Americans.
We found that obesity and the number of comorbidities
signiﬁcantly predicted abnormal GLS. Obesity has been
previously implicated as a substantial risk factor for LV
remodeling, and thus its relationship to GLS is not surpris-
ing.3,29 Previous studies have shown that individual comor-
bidities are associated with worse myocardial mechanics.30
However, to our knowledge, ours is the ﬁrst to comprehen-
sively quantitate the adverse effects of comorbidity burden.
Understanding the relationship between comorbidity burden,
in addition to individual comorbidities, and cardiac mechanics
is particularly clinically relevant, given the high number of
patients with multiple comorbidities. Determination of cardiac
mechanics may be a more sensitive and useful assay for
cardiovascular prevention. Further, our results demonstrate
the potential utility of examining the total number of
comorbidities in the cardiac assessment of patients, since
Table 7. Differences in Demographics and Comorbidities









Age, y 5413 4813 <0.001
Female, n (%) 588 (51) 660 (66) <0.001
Recruiting center, n (%) <0.001
Birmingham, AL 3 (<1) 587 (59)
Minneapolis, MN 425 (37) 0 (0)
Forsyth County, NC 584 (51) 0 (0)
Salt Lake City, UT 132 (12) 411 (41)
Number of comorbidities, n (%) 0.43
0 172 (15) 131 (13)
1 267 (23) 247 (25)
2 299 (26) 285 (29)
3 243 (21) 206 (21)
4 130 (11) 96 (10)




Individual comorbidities, n (%)
Hypertension 624 (55) 620 (63) <0.001
Dyslipidemia 798 (70) 507 (51) <0.001
Obesity 494 (43) 523 (52) <0.001
Diabetes mellitus 160 (14) 205 (21) <0.001
Chronic kidney disease 141 (12) 56 (6) <0.001
Myocardial infarction 74 (6) 57 (6) 0.46
Transient ischemic attack or
stroke
38 (3) 58 (6) 0.005
Table 8. Predictors of Abnormal Global Longitudinal Strain by
Comorbidity*
Comorbidity Odds Ratio (95% CI) P Value
Hypertension 1.35 (0.98, 1.85) 0.07
Dyslipidemia 1.21 (0.91, 1.59) 0.18
Obesity 1.31 (1.00, 1.72) 0.049
Diabetes mellitus 1.19 (0.85, 1.67) 0.32
Chronic kidney disease 1.52 (0.95, 2.43) 0.08
Myocardial infarction 1.42 (0.84, 2.39) 0.19
Transient ischemic attack or stroke 1.63 (0.92, 2.84) 0.08
Number of comorbidities 1.22 (1.08, 1.37) 0.0009
*Abnormal global longitudinal strain deﬁned as <12% (see text for details); Multivariable
mixed-effects logistic regression models were adjusted for speckle-tracking analyst,
recruiting center, image quality, age, sex, race, left ventricular mass index, wall motion
score, and ejection fraction.
Table 6. Association of Number of Comorbidities With Cardiac Mechanics and Filling Pressures After Multivariable Adjustment
(Model 2)—Race-Stratiﬁed Analyses*
Dependent Variable
White Participants (n=1144) African American Participants (n=998)
Race9Comorbidities
Interaction P Valueb-Coefﬁcient (95% CI) P Value b-Coefﬁcient (95% CI) P Value
Global radial strain, % 0.23 (0.86, 0.40) 0.48 0.69 (1.29, 0.09) 0.025 0.44
Global circumferential strain, % 0.11 (0.15, 0.36) 0.43 0.12 (0.38, 0.13) 0.34 0.003
Global longitudinal strain, % 0.23 (0.39, 0.07) 0.005 0.39 (0.57, 0.21) <0.0001 0.026
e’ velocity, cm/s 0.16 (0.22, 0.10) <0.0001 0.16 (0.22, 0.09) <0.0001 0.79
E/e’ ratio 1.26 (0.61, 1.92) <0.0001 1.95 (0.99, 2.91) <0.0001 <0.001
*Adjusted for speckle-tracking analyst, recruiting center, image quality, age, sex, left ventricular mass index, wall motion score, and ejection fraction.
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the number of comorbidities was the only signiﬁcant predictor
of abnormal GLS apart from obesity.
Interest in the role of comorbidities in cardiovascular
disease, speciﬁcally heart failure, is growing. The number of
comorbidities has recently been shown to predict heart failure
hospitalization, all-cause hospitalization, and death, particu-
larly in those with preserved ejection fraction.10,31 Of note, a
substantial percentage of patients with heart failure, regard-
less of ejection fraction, do not have evidence of antecedent
LV hypertrophy. The reduction in indices of cardiac mechanics
in participants with normal LV geometry observed in our study
may underlie this transition from multiple comorbidities to the
heart failure syndrome in the presence and absence of overt
LV remodeling.
The importance of worsening cardiac mechanics to
cardiovascular disease cannot be overemphasized. Changes
in tissue deformation often precede alterations observed in
traditional 2-dimensional echocardiography. Thus, a “normal”
echocardiogram may not be as reassuring in the context of
abnormal cardiac mechanics. In addition, GLS, in particular, is
an independent predictor of all-cause mortality and is superior
to conventional echocardiographic indices such as the
ejection fraction or wall motion score index.24 Though still
an emerging tool in cardiovascular imaging, speckle-tracking
echocardiography may highlight the highest risk individuals,
including those with high comorbidity burden.
Our results should be interpreted in the context of a few
limitations. First, the cross-sectional design of our study
precludes our ability to determine whether the reductions in
cardiac mechanics as a consequence of comorbidity burden
result in adverse outcomes. Second, some of the comorbid-
ities were obtained only by self-reported history. Third,
speckle-tracking was performed on archival echocardiograms
stored on videotapes that may have degraded image quality.25
However, the vast majority of images acquired were of good
or high quality; in addition, image quality was entered into all
regression analyses. Fourth, we were unable to adjust for
preload in our analyses, which may inﬂuence cardiac
mechanics, since this echocardiographic data is not available
in HyperGEN. Finally, the deﬁnition of abnormal GLS was
based off measurements using a different software package,
EchoPAC. However, there is low inter-platform variability
when compared with TomTec speckle-tracking software.32
In conclusion, comorbidity burden is associated with a
worse cardiac mechanics and higher LV-ﬁlling pressures in a
dose-response fashion, even in those with normal LV geom-
etry and particularly in African Americans. Obesity and the
number of comorbidities are signiﬁcantly associated with the
presence of abnormal strain. The deleterious effect of multiple
comorbidities on cardiac mechanics may explain both the
high comorbidity burden and adverse outcomes in patients
who ultimately develop heart failure. Whether treatment of
comorbidities improves cardiac mechanics and/or outcomes
should be evaluated prospectively.
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